Key facts
- A U.S. appeals court revived some consumer claims against drugmakers and retailers over decongestants.
- The court found that "maximum strength" labels on decongestants could be subject to litigation.
- Drugs approved via the New Drug Application process may also be litigated.
- A U.S. appeals court found Enbridge liable for trespass on tribal land in northern Wisconsin.
- Enbridge must reroute a pipeline that trespassed on tribal land.
- The deadline for Enbridge to reroute the pipeline has been extended.
- The court ordered a recalculation of damages owed by Enbridge.
A U.S. appeals court has revived certain consumer claims against drugmakers and retailers regarding over-the-counter decongestants. The court ruled that labels stating "maximum strength" and drugs approved through the New Drug Application (NDA) process could still be subject to litigation. This decision allows consumers to pursue claims that these labels were misleading.
In a separate development, a U.S. appeals court found Enbridge liable for trespass on land belonging to a northern Wisconsin tribe. The pipeline company operated a pipeline under tribal land without proper authorization. The court has extended the deadline for Enbridge to reroute the pipeline and has ordered a recalculation of the damages owed to the tribe. The specific tribe and the exact location of the land were not detailed in the provided information.